{
    "nct_id": "NCT05626322",
    "official_title": "A PHASE 1b/2 STUDY OF PF-07901801, A CD47 BLOCKING AGENT, WITH TAFASITAMAB AND LENALIDOMIDE FOR PARTICIPANTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION",
    "inclusion_criteria": "* Histologically confirmed diagnosis of DLBCL\n* Relapsed or refractory disease\n* Participant is not be a candidate for or is unwilling to undergo high dose chemotherapy and subsequent stem cell transplant and/or is unable to receive chimeric antigen receptor (CAR) T-cell therapy\n* Previous treatment with at least one prior line of systemic therapy (for phase 2, at least 1 and no more than 2 prior lines of systemic therapy). Prior therapy must include an anti-CD20 antibody.\n* Adequate bone marrow, hepatic and renal function\n* Eastern Cooperative Oncology Group (ECOG) â‰¤2\n* Must provide a tumor tissue sample (fresh or archival, collected prior to start of treatment) for biomarker analysis\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior treatment with an anti-CD47 or anti-CD19 (other than CAR T) or immunomodulatory agents\n* Prior allogeneic stem cell transplantation or autologous stem cell transplantation within 12 weeks prior to enrolment\n* Participants with active, uncontrolled bacterial, fungal or viral infection.",
    "miscellaneous_criteria": "Key"
}